• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Overall survival in MERiDiAN, a double-blind placebo-controlled randomised phase III trial evaluating first-line bevacizumab plus paclitaxel for HER2-negative metastatic breast cancer.

作者信息

Miles David, Cameron David, Hilton Magalie, Garcia Josep, O'Shaughnessy Joyce

机构信息

Mount Vernon Cancer Centre, Rickmansworth Road, Northwood, London, HA6 2RN, UK.

University of Edinburgh and Cancer Services, NHS Lothian, Western General Hospital, Crewe Road South, Edinburgh, EH4 2XU, UK.

出版信息

Eur J Cancer. 2018 Feb;90:153-155. doi: 10.1016/j.ejca.2017.10.018. Epub 2017 Nov 23.

DOI:10.1016/j.ejca.2017.10.018
PMID:29174181
Abstract
摘要

相似文献

1
Overall survival in MERiDiAN, a double-blind placebo-controlled randomised phase III trial evaluating first-line bevacizumab plus paclitaxel for HER2-negative metastatic breast cancer.MERiDiAN研究中的总生存期，这是一项双盲、安慰剂对照的随机III期试验，评估一线贝伐单抗联合紫杉醇用于HER2阴性转移性乳腺癌的疗效。
Eur J Cancer. 2018 Feb;90:153-155. doi: 10.1016/j.ejca.2017.10.018. Epub 2017 Nov 23.
2
Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation.贝伐单抗联合紫杉醇对比安慰剂联合紫杉醇作为HER2阴性转移性乳腺癌的一线治疗（MERiDiAN）：一项具有前瞻性生物标志物评估的双盲安慰剂对照随机III期试验。
Eur J Cancer. 2017 Jan;70:146-155. doi: 10.1016/j.ejca.2016.09.024. Epub 2016 Nov 4.
3
Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial.贝伐珠单抗联合紫杉醇对比贝伐珠单抗联合卡培他滨作为 HER2 阴性转移性乳腺癌一线治疗（TURANDOT）：一项随机、开放标签、非劣效性、III 期临床试验的主要终点结果。
Lancet Oncol. 2016 Sep;17(9):1230-9. doi: 10.1016/S1470-2045(16)30154-1. Epub 2016 Aug 5.
4
First-line bevacizumab plus paclitaxel in Japanese patients with HER2-negative metastatic breast cancer: subgroup results from the randomized Phase III MERiDiAN trial.一线贝伐单抗联合紫杉醇用于日本HER2阴性转移性乳腺癌患者：随机III期MERiDiAN试验的亚组结果
Jpn J Clin Oncol. 2017 May 1;47(5):385-392. doi: 10.1093/jjco/hyx001.
5
Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study.莫特沙尼（Motesanib），或开放标签贝伐珠单抗，联合紫杉醇，作为 HER2 阴性局部复发性或转移性乳腺癌的一线治疗：一项 2 期、随机、双盲、安慰剂对照研究。
Lancet Oncol. 2011 Apr;12(4):369-76. doi: 10.1016/S1470-2045(11)70037-7. Epub 2011 Mar 21.
6
Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial.贝伐珠单抗联合紫杉醇对比贝伐珠单抗联合卡培他滨作为 HER2 阴性转移性乳腺癌一线治疗：随机、开放标签、非劣效性、III 期 TURANDOT 试验的中期疗效结果。
Lancet Oncol. 2013 Feb;14(2):125-33. doi: 10.1016/S1470-2045(12)70566-1. Epub 2013 Jan 10.
7
Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.依维莫司联合曲妥珠单抗和紫杉醇一线治疗人表皮生长因子受体 2 阳性晚期乳腺癌（BOLERO-1）：一项 III 期、随机、双盲、多中心试验。
Lancet Oncol. 2015 Jul;16(7):816-29. doi: 10.1016/S1470-2045(15)00051-0. Epub 2015 Jun 16.
8
SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial.SAKK 24/09：贝伐单抗联合紫杉醇与贝伐单抗联合节拍性环磷酰胺及卡培他滨作为HER2阴性晚期乳腺癌患者一线治疗的安全性和耐受性——一项多中心、随机III期试验
BMC Cancer. 2016 Oct 10;16(1):780. doi: 10.1186/s12885-016-2823-y.
9
RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.RIBBON-2 研究：一项随机、双盲、安慰剂对照的 III 期临床试验，旨在评估贝伐珠单抗联合化疗二线治疗人表皮生长因子受体 2 阴性转移性乳腺癌的疗效和安全性。
J Clin Oncol. 2011 Nov 10;29(32):4286-93. doi: 10.1200/JCO.2010.34.1255. Epub 2011 Oct 11.
10
Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial.贝伐珠单抗联合化疗对比化疗作为一线治疗联合贝伐珠单抗化疗后 HER2 阴性局部复发或转移性乳腺癌患者的二线治疗（TANIA）：一项开放标签、随机 3 期试验。
Lancet Oncol. 2014 Oct;15(11):1269-78. doi: 10.1016/S1470-2045(14)70439-5. Epub 2014 Sep 28.

引用本文的文献

1
Paclitaxel plus Eftilagimod Alpha, a Soluble LAG-3 Protein, in Metastatic, HR+ Breast Cancer: Results from AIPAC, a Randomized, Placebo Controlled Phase IIb Trial.紫杉醇联合艾弗他吉莫德α（一种可溶性LAG-3蛋白）用于治疗转移性HR+乳腺癌：AIPAC研究结果，一项随机、安慰剂对照的IIb期试验
Clin Cancer Res. 2024 Feb 1;30(3):532-541. doi: 10.1158/1078-0432.CCR-23-1173.
2
Factors affecting prognosis in patients treated with bevacizumab plus paclitaxel as first-line chemotherapy for HER2-negative metastatic breast cancer: an international pooled analysis of individual patient data from four prospective observational studies.贝伐珠单抗联合紫杉醇作为一线化疗治疗 HER2 阴性转移性乳腺癌患者预后的影响因素：四项前瞻性观察性研究中个体患者数据的国际汇总分析。
Breast Cancer. 2023 Jan;30(1):88-100. doi: 10.1007/s12282-022-01399-1. Epub 2022 Sep 3.
3
The cancer angiogenesis co-culture assay: In vitro quantification of the angiogenic potential of tumoroids.肿瘤类器官共培养的血管生成分析：体外定量评估肿瘤类器官的血管生成潜能。
PLoS One. 2021 Jul 7;16(7):e0253258. doi: 10.1371/journal.pone.0253258. eCollection 2021.
4
Systemic immunity markers associated with lymphocytes predict the survival benefit from paclitaxel plus bevacizumab in HER2 negative advanced breast cancer.与淋巴细胞相关的系统性免疫标志物可预测曲妥珠单抗联合贝伐珠单抗治疗 HER2 阴性晚期乳腺癌的生存获益。
Sci Rep. 2021 Mar 18;11(1):6328. doi: 10.1038/s41598-021-85948-2.
5
Efficacy and Safety of Bevacizumab-Combined Chemotherapy for Advanced and Recurrent Endometrial Cancer: A Systematic Review and Meta-analysis.贝伐珠单抗联合化疗治疗晚期和复发性子宫内膜癌的疗效和安全性：系统评价和荟萃分析。
Balkan Med J. 2021 Jan;38(1):7-12. doi: 10.5152/balkanmedj.2021.20121. Epub 2020 Nov 2.
6
Prospective observational study of bevacizumab combined with paclitaxel as first- or second-line chemotherapy for locally advanced or metastatic breast cancer: the JBCRG-C05 (B-SHARE) study.贝伐珠单抗联合紫杉醇作为局部晚期或转移性乳腺癌一线或二线化疗的前瞻性观察研究：JBCRG-C05（B-SHARE）研究。
Breast Cancer. 2021 Jan;28(1):145-160. doi: 10.1007/s12282-020-01138-4. Epub 2020 Jul 26.
7
Bevacizumab as First-line Treatment for HER2-negative Advanced Breast Cancer: Paclitaxel plus Bevacizumab Other Chemotherapy.贝伐珠单抗作为一线治疗方案用于曲妥珠单抗治疗失败的 HER2 阴性晚期乳腺癌：紫杉醇联合贝伐珠单抗与其他化疗药物。
In Vivo. 2020 May-Jun;34(3):1377-1386. doi: 10.21873/invivo.11917.
8
Baseline neutrophil-to-lymphocyte ratio and c-reactive protein predict efficacy of treatment with bevacizumab plus paclitaxel for locally advanced or metastatic breast cancer.基线中性粒细胞与淋巴细胞比值及C反应蛋白可预测贝伐单抗联合紫杉醇治疗局部晚期或转移性乳腺癌的疗效。
Oncotarget. 2020 Jan 7;11(1):86-98. doi: 10.18632/oncotarget.27423.
9
Toxicity of locoregional radiotherapy in combination with bevacizumab in patients with non-metastatic breast cancer (TOLERAB): Final long-term evaluation.局部区域放疗联合贝伐珠单抗治疗非转移性乳腺癌患者的毒性（TOLERAB）：最终长期评估。
PLoS One. 2019 Aug 30;14(8):e0221816. doi: 10.1371/journal.pone.0221816. eCollection 2019.
10
Can contemporary trials of chemotherapy for HER2-negative metastatic breast cancer detect overall survival benefit?当代针对HER2阴性转移性乳腺癌的化疗试验能否检测出总生存获益？
Cancer Manag Res. 2018 Nov 8;10:5423-5431. doi: 10.2147/CMAR.S177240. eCollection 2018.